此外，公司已成功以较低利率的银行贷款为CRM业务的可换股债券进行再融资，进一步巩固其财务状 况。再融资安排将降低公司的融资成本，从而支持公司实现同比收窄净亏损的目标，并达成2026财年净 利润9000万美元的目标。 摩根大通发布研报称，预期微创医疗(00853)股价将有正面反应，重申对微创医疗的"增持"评级，现予 目标价18.2港元。公司已就将其心律管理业务(CRM)与心通医疗-B(02160)合并达成最终协议。该行认为 交易顺利完成，有助消除持续困扰公司的重大不明朗因素。 ...

此外，公司已成功以较低利率的银行贷款为CRM业务的可换股债券进行再融资，进一步巩固其财务状 况。再融资安排将降低公司的融资成本，从而支持公司实现同比收窄净亏损的目标，并达成2026财年净 利润9000万美元的目标。 智通财经APP获悉，摩根大通发布研报称，预期微创医疗(00853)股价将有正面反应，重申对微创医疗 的"增持"评级，现予目标价18.2港元。公司已就将其心律管理业务(CRM)与心通医疗-B(02160)合并达成 最终协议。该行认为交易顺利完成，有助消除持续困扰公司的重大不明朗因素。 ...

Core Viewpoint - Bank of America Securities has initiated coverage on MicroPort Medical (00853) with a "Buy" rating and a target price of HKD 16.8, citing the elimination of recent liquidity pressures and a shift in investor focus back to fundamentals [1] Financial Performance - The company is expected to achieve profitability by the first half of 2026 through cost control and divestment of non-core assets [1] - Revenue projections for 2025, 2026, and 2027 are USD 1.109 billion, USD 1.241 billion, and USD 1.407 billion, representing year-on-year growth rates of 7.6%, 11.9%, and 13.3% respectively [1] Strategic Developments - The introduction of Shanghai Industrial, a state-owned enterprise, as a strategic shareholder is anticipated to support the company's financial and business development [1] - Rapid growth in overseas business is expected to mitigate domestic market risks and provide long-term growth visibility [1] Operational Efficiency - The company is projected to further reduce operating expense ratios and financing costs [1]

Core Viewpoint - Bank of America Securities has initiated coverage on MicroPort Medical (00853) with a "Buy" rating and a target price of HKD 16.8, citing the elimination of recent liquidity pressures and a shift in investor focus back to fundamentals [1] Group 1: Financial Performance and Projections - The company is expected to achieve profitability by the first half of 2026 through cost control and divestment of non-core assets [1] - Revenue projections for 2025, 2026, and 2027 are USD 1.109 billion, USD 1.241 billion, and USD 1.407 billion, representing year-on-year growth rates of 7.6%, 11.9%, and 13.3% respectively [1] Group 2: Strategic Developments - The introduction of Shanghai Industrial, a state-owned enterprise, as a strategic shareholder is anticipated to support the company's financial and business development [1] - Rapid growth in overseas business is expected to mitigate domestic market risks and provide long-term growth visibility [1] Group 3: Cost Management - The company is projected to further reduce operating expense ratios and financing costs [1]

该行预测2025至27年收入分别为11.09亿、12.41亿及14.07亿美元，相当于按年增长7.6%、11.9%与 13.3%，动力来自海外业务加速扩张及新产品上市；同时料营运开支比率和融资成本会进一步降低。 美银证券重新覆盖微创医疗，予"买入"评级，目标价16.8港元，因公司近期的流动性压力已消除，投资 者关注点由流动性风险回归到基本面。公司引入国企背景的上海实业作为战略股东，将支持财务与业务 发展。该行预期，通过成本控制与处置非核心资产，公司有望于2026年上半年实现盈利。另外，海外业 务快速增长，亦可分散国内市场风险，并提供长远增长能见度。 ...

Core Viewpoint - The article highlights the collective rise of the MicroPort group stocks following the announcement of MicroPort Medical's restructuring of its cardiac rhythm management business, which aims to alleviate pressure related to meeting listing standards [1] Group 1: Stock Performance - MicroPort Medical (00853) increased by 8.47%, reaching HKD 14.21 [1] - HeartLink Medical-B (02160) rose by 4.55%, reaching HKD 1.38 [1] - MicroPort Robotics-B (02252) saw a 4.28% increase, reaching HKD 28.26 [1] - MicroPort Neuroscience (02172) grew by 2.88%, reaching HKD 12.52 [1] Group 2: Business Restructuring - MicroPort Medical announced the restructuring of its cardiac rhythm management business, with its subsidiary MicroPort HeartLink planning to merge with CRM Cayman [1] - Upon completion of the merger, CRM Cayman will become a wholly-owned subsidiary of MicroPort HeartLink, focusing on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is reported to be USD 680 million [1] Group 3: Ownership and Investment - MicroPort Medical currently holds a 46.12% stake in HeartLink Medical and a 50.13% stake in CRM Cayman [1] - In July 2021, Hillhouse Capital, along with CPE and Springhill, invested USD 300 million in MicroPort's cardiac rhythm management subsidiary, acquiring a 26.3% stake [1] - There is an agreement that if CRM Cayman does not achieve a qualified listing and a market value of at least USD 1.5 billion by July 17, 2025, MicroPort must repurchase all shares at an annualized return of 8% [1]

Core Viewpoint - The stocks of the MicroPort group have collectively risen, driven by the announcement of a restructuring in the cardiac rhythm management business, which aims to alleviate pressure related to meeting listing standards [1] Group 1: Stock Performance - MicroPort Medical (00853) increased by 8.47%, reaching HKD 14.21 [1] - HeartLink Medical-B (02160) rose by 4.55%, reaching HKD 1.38 [1] - MicroPort Robotics-B (02252) saw a 4.28% increase, reaching HKD 28.26 [1] - MicroPort Neuroscience (02172) grew by 2.88%, reaching HKD 12.52 [1] Group 2: Business Restructuring - MicroPort Medical announced the restructuring of its cardiac rhythm management business, with a subsidiary, MicroPort HeartLink, planning to merge with CRM Cayman [1] - Post-merger, CRM Cayman will become a wholly-owned subsidiary of MicroPort HeartLink, focusing on solutions for arrhythmia management, with a pre-transaction equity value of USD 680 million [1] - MicroPort Medical currently holds a 46.12% stake in HeartLink Medical and a 50.13% stake in CRM Cayman [1] Group 3: Strategic Intent - The restructuring is seen as a strategy to mitigate the pressure of meeting the "qualified listing" requirements for the cardiac rhythm management business [1] - In July 2021, Hillhouse Capital, along with CPE and Springhill, invested USD 300 million in MicroPort's cardiac rhythm management subsidiary, acquiring a 26.3% stake [1] - An agreement was made that if CRM does not achieve a qualified listing and a market value of at least USD 1.5 billion by July 17, 2025, MicroPort must repurchase all shares at an annualized return of 8% [1]

目标集团主要从事CRM业务，专注于管理心律失常的解决方案。其提供监测患者心脏资讯的设备，以 便识别异常的心脏状况，如心动过缓及快速性心律失常;以及应用电脉冲和电击来预防或治疗有关异常 状况或提供心脏再同步化治疗。 董事认为，交易符合本集团业务的战略发展，将有助于本集团建立具备全球影响力的心脏病产品平台， 以提供多元化产品及产品管线，并实现互补协同效应。交易所产生的有关协同效应将扩大及多元化本集 团现有业务，尤其是强化本集团在结构性心脏病及CRM解决方案的产品及管线，同时提升研发能力、 生产能力、分销渠道及市场扩张能力。 根据合并协议的条款及条件以及遵照开曼《公司法》，本公司将以合并方式收购目标公司，合并附属公 司及目标公司将于生效时间合并并作为一家公司存续，且目标公司于合并后作为本公司的间接全资附属 公司存续，作为代价，本公司将向目标公司股东配发及发行新股份。于合并完成后，目标集团的成员公 司将成为本公司的间接附属公司，且目标集团的财务业绩将并入本集团的财务业绩。 目标公司协定价值为6.8亿美元，乃由本公司与目标公司经参考仲量联行企业评估及谘询有限公司进行 的估值后公平磋商厘定。 心通医疗-B(02160)发 ...

Group 1 - The company, HeartLink Medical-B (02160), announced a merger agreement with MicroPort CardioFlow CRM Limited and the target company, MicroPort Medical (00853), to acquire the target company for a valuation of $680 million [1] - The merger will result in the target company becoming an indirect wholly-owned subsidiary of HeartLink Medical, with its financial performance being consolidated into the group's financial results [1] - The target company specializes in CRM solutions, providing devices to monitor cardiac information and manage arrhythmias, including treatments for bradycardia and tachyarrhythmias [1] Group 2 - The board believes the transaction aligns with the group's strategic development, aiming to establish a globally influential cardiac product platform with a diversified product line [2] - The synergies generated from the transaction are expected to enhance and diversify the existing business, particularly strengthening the group's offerings in structural heart disease and CRM solutions [2] - The merger is anticipated to improve the company's R&D capabilities, production capacity, distribution channels, and market expansion efforts [2]

Group 1 - The core transaction involves MicroPort Cardio Flow CRM Limited acquiring CRM Cayman through a merger agreement, with CRM Cayman becoming a wholly-owned subsidiary of MicroPort Cardio Flow upon completion [1][2] - The merger will involve the issuance of new shares at a price of HKD 1.35 per share to CRM Cayman shareholders, with a pre-transaction equity value of CRM Cayman estimated at USD 680 million [1][2] - The merger is strategically aligned with MicroPort Cardio Flow's business development, aiming to establish a global cardiac product platform and enhance its product offerings and capabilities in structural heart disease and arrhythmia management [2] Group 2 - CRM Cayman and its subsidiaries focus on arrhythmia management solutions, providing devices to monitor heart conditions and deliver treatments [2] - MicroPort Cardio Flow specializes in innovative transcatheter solutions for structural heart disease, with products including valve products and left atrial appendage occluders [2] - The merger is expected to create complementary synergies that will diversify and expand MicroPort Cardio Flow's existing business, particularly in research and development, manufacturing, distribution channels, and market expansion [2]